Treatment of 4TOO plasmacytoma with FC/4TOO vaccination and IL-12.
Immunization schedule for the intravenous injection of 4TOO and FC/4TOO cells combined with intraperitoneal administration of IL-12. (A) Balb/c mice (10 per group) were injected intravenously with 1 × 106 4TOO cells on day 0 and then treated with IL-12 (500 ng/dose) and FC/4TOO cells (●) as outlined in the schedule. The mice were also treated with 1 × 106 irradiated 4TOO cells (□), FC/4TOO (■), or IL-12 (○; 500 ng/dose) alone. (B) Splenocytes from mice treated as described in (A) were harvested on day 16. The T cells were purified by nylon wool column and incubated with 4TOO targets at the indicated ratios. CTL activity was determined by the 51Cr release assay. (C) Balb/c mice (10 per group) were injected with 1 × 106 4TOO cells on day 0 and then treated with IL-12 (200 μg/dose) and FC/4TOO cells (●). Mice treated with 1 × 106 irradiated 4TOO (▵), FC/4TOO cells (■), or IL-12 alone (○; 200 ng/dose) were used as controls. (D) Splenocytes from mice treated as described in (C) were isolated on day 16 and incubated with 4TOO targets at the indicated ratios. CTL activity was determined by the 51Cr release assay. Similar results were obtained in 2 separate experiments.
